These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

337 related items for PubMed ID: 14872180

  • 1. Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents.
    Bergen R, Black S, Shinefield H, Lewis E, Ray P, Hansen J, Walker R, Hessel C, Cordova J, Mendelman PM.
    Pediatr Infect Dis J; 2004 Feb; 23(2):138-44. PubMed ID: 14872180
    [Abstract] [Full Text] [Related]

  • 2. Safety and tolerability of cold-adapted influenza vaccine, trivalent, in infants younger than 6 months of age.
    Vesikari T, Karvonen A, Smith HM, Dunning A, Razmpour A, Saville MK, Gruber WC, Forrest BD.
    Pediatrics; 2008 Mar; 121(3):e568-73. PubMed ID: 18299305
    [Abstract] [Full Text] [Related]

  • 3. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma.
    Fleming DM, Crovari P, Wahn U, Klemola T, Schlesinger Y, Langussis A, Øymar K, Garcia ML, Krygier A, Costa H, Heininger U, Pregaldien JL, Cheng SM, Skinner J, Razmpour A, Saville M, Gruber WC, Forrest B, CAIV-T Asthma Study Group.
    Pediatr Infect Dis J; 2006 Oct; 25(10):860-9. PubMed ID: 17006278
    [Abstract] [Full Text] [Related]

  • 4. Safety, efficacy, and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population aged 5-49 years.
    Belshe RB, Nichol KL, Black SB, Shinefield H, Cordova J, Walker R, Hessel C, Cho I, Mendelman PM.
    Clin Infect Dis; 2004 Oct 01; 39(7):920-7. PubMed ID: 15472840
    [Abstract] [Full Text] [Related]

  • 5. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections.
    Ashkenazi S, Vertruyen A, Arístegui J, Esposito S, McKeith DD, Klemola T, Biolek J, Kühr J, Bujnowski T, Desgrandchamps D, Cheng SM, Skinner J, Gruber WC, Forrest BD, CAIV-T Study Group.
    Pediatr Infect Dis J; 2006 Oct 01; 25(10):870-9. PubMed ID: 17006279
    [Abstract] [Full Text] [Related]

  • 6. Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children.
    Piedra PA, Gaglani MJ, Kozinetz CA, Herschler GB, Fewlass C, Harvey D, Zimmerman N, Glezen WP.
    Pediatrics; 2007 Sep 01; 120(3):e553-64. PubMed ID: 17698577
    [Abstract] [Full Text] [Related]

  • 7. Safety, efficacy and effectiveness of cold-adapted, live, attenuated, trivalent, intranasal influenza vaccine in adults and children.
    Belshe RB, Gruber WC.
    Philos Trans R Soc Lond B Biol Sci; 2001 Dec 29; 356(1416):1947-51. PubMed ID: 11779396
    [Abstract] [Full Text] [Related]

  • 8. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children.
    Belshe RB, Mendelman PM, Treanor J, King J, Gruber WC, Piedra P, Bernstein DI, Hayden FG, Kotloff K, Zangwill K, Iacuzio D, Wolff M.
    N Engl J Med; 1998 May 14; 338(20):1405-12. PubMed ID: 9580647
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of a live attenuated, cold-adapted influenza vaccine, trivalent against culture-confirmed influenza in young children in Asia.
    Tam JS, Capeding MR, Lum LC, Chotpitayasunondh T, Jiang Z, Huang LM, Lee BW, Qian Y, Samakoses R, Lolekha S, Rajamohanan KP, Narayanan SN, Kirubakaran C, Rappaport R, Razmpour A, Gruber WC, Forrest BD, Pan-Asian CAIV-T Pediatric Efficacy Trial Network.
    Pediatr Infect Dis J; 2007 Jul 14; 26(7):619-28. PubMed ID: 17596805
    [Abstract] [Full Text] [Related]

  • 10. Safety, efficacy, and effectiveness of cold-adapted influenza vaccine-trivalent against community-acquired, culture-confirmed influenza in young children attending day care.
    Vesikari T, Fleming DM, Aristegui JF, Vertruyen A, Ashkenazi S, Rappaport R, Skinner J, Saville MK, Gruber WC, Forrest BD, CAIV-T Pediatric Day Care Clinical Trial Network.
    Pediatrics; 2006 Dec 14; 118(6):2298-312. PubMed ID: 17142512
    [Abstract] [Full Text] [Related]

  • 11. Cold-adapted, live attenuated influenza vaccine.
    Glezen WP.
    Expert Rev Vaccines; 2004 Apr 14; 3(2):131-9. PubMed ID: 15056039
    [Abstract] [Full Text] [Related]

  • 12. Live attenuated influenza vaccine in children.
    Ambrose CS, Walker RE, Connor EM.
    Semin Pediatr Infect Dis; 2006 Oct 14; 17(4):206-12. PubMed ID: 17055372
    [Abstract] [Full Text] [Related]

  • 13. Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age.
    Nolan T, Bernstein DI, Block SL, Hilty M, Keyserling HL, Marchant C, Marshall H, Richmond P, Yogev R, Cordova J, Cho I, Mendelman PM, LAIV Study Group.
    Pediatrics; 2008 Mar 14; 121(3):508-16. PubMed ID: 18310199
    [Abstract] [Full Text] [Related]

  • 14. Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial.
    Piedra PA, Gaglani MJ, Riggs M, Herschler G, Fewlass C, Watts M, Kozinetz C, Hessel C, Glezen WP.
    Pediatrics; 2005 Sep 14; 116(3):e397-407. PubMed ID: 16140685
    [Abstract] [Full Text] [Related]

  • 15. Safety of the trivalent, cold-adapted influenza vaccine in preschool-aged children.
    Piedra PA, Yan L, Kotloff K, Zangwill K, Bernstein DI, King J, Treanor J, Munoz F, Wolff M, Cho I, Mendelman PM, Cordova J, Belshe RB.
    Pediatrics; 2002 Oct 14; 110(4):662-72. PubMed ID: 12359778
    [Abstract] [Full Text] [Related]

  • 16. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants.
    Karron RA, Belshe RB, Wright PF, Thumar B, Burns B, Newman F, Cannon JC, Thompson J, Tsai T, Paschalis M, Wu SL, Mitcho Y, Hackell J, Murphy BR, Tatem JM.
    Pediatr Infect Dis J; 2003 May 14; 22(5):394-405. PubMed ID: 12792378
    [Abstract] [Full Text] [Related]

  • 17. Shedding of Ann Arbor strain live attenuated influenza vaccine virus in children 6-59 months of age.
    Mallory RM, Yi T, Ambrose CS.
    Vaccine; 2011 Jun 10; 29(26):4322-7. PubMed ID: 21513761
    [Abstract] [Full Text] [Related]

  • 18. Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.
    Drugs R D; 2003 Jun 10; 4(5):312-9. PubMed ID: 12952502
    [Abstract] [Full Text] [Related]

  • 19. A randomized, double-blind study of the safety, transmissibility and phenotypic and genotypic stability of cold-adapted influenza virus vaccine.
    Vesikari T, Karvonen A, Korhonen T, Edelman K, Vainionpää R, Salmi A, Saville MK, Cho I, Razmpour A, Rappaport R, O'Neill R, Georgiu A, Gruber W, Mendelman PM, Forrest B, CAIV-T Transmission Study Group.
    Pediatr Infect Dis J; 2006 Jul 10; 25(7):590-5. PubMed ID: 16804427
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of a single dose of live attenuated influenza vaccine in previously unvaccinated children: a post hoc analysis of three studies of children aged 2 to 6 years.
    Block SL, Toback SL, Yi T, Ambrose CS.
    Clin Ther; 2009 Oct 10; 31(10):2140-7. PubMed ID: 19922885
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.